Anti-TNFα Drugs (Biologics)

The Reference Chemistry Laboratory at Viapath, Guy’s and St Thomas’ Hospital is the first to introduce anti-TNFα and anti-drug antibody testing in the UK. Our service is backed by innovative research in collaboration with the Gastroenterology and Dermatology clinical teams at GSTT. The introduction of anti-TNFα drug and anti-drug antibody monitoring may allow clinicians to personalise therapy for better patient care and associated savings on drug costs.

**TNFα antagonists (biologic drugs):**
NICE guidance makes recommendations about the use of biologic drugs based on clinical and cost-effectiveness. Biologic drugs are recommended for the treatment of inflammatory disease in Rheumatology, Dermatology and Gastroenterology but restricted to patients who have an active, and moderate or severe form of their inflammatory condition, and who have contraindications to or whose condition is not responding to conventional treatments and/or pharmacotherapy.

**Infliximab (Remicade®):** Infliximab is a TNFα blocker indicated for inflammatory bowel disease (incorporating Crohn’s disease and ulcerative colitis), rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

**Adalimumab (Humira®):** Adalimumab is a TNFα blocker indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and Crohn’s disease.

**Etanercept (Enbrel®):** Etanercept is a TNFα blocker indicated for rheumatoid arthritis, spondylitis, psoriatic arthritis, plaque psoriasis, juvenile arthritis and other rheumatic conditions.

**Immunogenicity of anti-TNFα drugs:**
Biologics are highly effective at inducing and maintaining remission however significant proportion of patients will not respond or will lose response.

- Patients can develop antibodies against the drug which neutralise the therapeutic effect of the anti-TNFα drug.
- Sub therapeutic levels of drug correlate to loss of response
- Measurement of drug and anti-drug antibody levels may aid individualisation of therapy

**Clinical indications for measurement* may include:**
- Primary treatment failure (non-response)
- Secondary loss of response
- Prediction of infusion reactions
- Adherence to therapy
- Reintroduction after drug interruption

* Please note that clinical validity and utility in psoriasis is not established and is currently subjected to research.

**A quick guide to personalising anti-TNFα therapy:**
Drug effectiveness based on drug and anti-drug antibody levels and clinical response:

- **Good response** - therapeutic levels of drug and no anti-drug antibody detected
- **Limited clinical response** - sub-therapeutic levels of drug and no anti-drug antibody detected; **consider dose escalation** OR sub-therapeutic levels of drug and high levels of anti-drug antibody detected; **may suggest the drug no longer effective for the patient, consider change anti-TNFα agent although may also be worth considering adding an immunomodulator**
- **No response** - therapeutic levels of drug; **disease activity may not be TNF-dependent and/or symptoms may not be due to active disease, suggest change drug type or look for alternative cause of symptoms**

Please note test interpretation requires full clinical information
| **Synonyms/ Key words** | Infliximab (Remicade®) and Anti-Infliximab Antibodies  
Adalimumab (Humira®) and Anti-Adalimumab antibodies  
Etanercept (Enbrel®) and Anti-Etanercept antibodies  
Certolizumab Pegol (Cimzia®), HACA |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test description</strong></td>
<td>Automated ELISA assay for the simultaneous analysis of both anti-TNFα drug and anti-drug antibody. The assays allows detection of the free anti-TNFα drugs currently prescribed, including Infliximab, Adalimumab, Etanercept and Certolizumab</td>
</tr>
<tr>
<td><strong>Laboratory Service</strong></td>
<td>Reference Chemistry, Biochemical Sciences, St Thomas’ Hospital</td>
</tr>
<tr>
<td><strong>Address to send to</strong></td>
<td>SP Unit, 5th Floor, North Wing, St Thomas’ Hospital, Lambeth Palace Road, London, SE1 7EH (Tel: 020 7188 3242)</td>
</tr>
</tbody>
</table>
| **Clinical Contacts** | Ms Zehra Arkir  
Tel: 020 7188 1253 Email: Zehra.Arkir@viapath.co.uk  
Mr Nick Unsworth or Mrs Gillian Richards  
Tel: 020 7188 1264 Email: Gillian.Richards@viapath.co.uk or Nick.Unsworth@viapath.co.uk |
| **Chief Biomedical Scientist** | Mark Dunsford  
Tel: 020 7188 1523 |
| **Download Referral Form** | Email or call clinical contacts for referral form |
| **Sample required** | Serum sample required. Collect blood into a serum separation (SST™) or plain tube, preferably shortly before drug administration (tough levels for infliximab). |
| **-Additional Information/Special sample instructions** | Centrifuge sample at 3000 rpm for 10 minutes, aliquot serum and keep in fridge until transport. If transport is going to be delayed over 5 days freeze at -20°C. Post the sample to GSTS by first class post. Minimum 300µL serum required for both drug and anti-drug antibody analysis. |
| **Turnround Time** | < 2 weeks |
| **Interpretation** | Tailored interpretation based on clinical history |
| **Call in advance** | For Certolizumab requests only. Email or call clinical contacts. |
| **Cost** | On application (discounts could be available for significant workloads) |